FOLD stock news

Amicus Therapeutics (FOLD) today announced additional positive results from a global Phase 1/2 clinical study (ATB200-02) to investigate AT-GAA in adult patients with Pompe disease, an inherited lysosomal storage disorder caused by an enzyme deficiency that leads to accumulation of glycogen (disease Read more
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 26.) AstraZeneca plc (NYSE: AZN ) GlaxoSmithKline plc (NYSE: GSK ) Sanofi SA (NASDAQ: SNY ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Down In The Dumps (Biotech stocks that hit 52-week lows Sept. 26.) ABIOMED, Inc. (NASDAQ: ABMD ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Aduro BioTech Inc (NASDAQ: ADRO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) AnaptysBio Inc (NASDAQ: ANAB ) Aridis Pharmaceuticals Inc (NASDAQ: ARDS ) AzurRx BioPharma Inc (NASDAQ: AZRX ) Bellerophon Therapeutics Inc (NASDAQ: BLPH ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) (announced submission of clinical trial application to U.K. regulators for its investigational therapy for phenylketonuria) BioNano Genomics Inc (NASDAQ: BNGO ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Calithera Biosciences Inc (NASDAQ: CALA ) Catalyst Biosciences Inc (NASDAQ: CBIO ) Cellectis SA (NASDAQ: CLLS ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Corvus Pharmaceuticals Inc (NASDAQ: CRVS ) CytomX Therapeutics Inc (NASDAQ: CTMX ) strong>DiaMedica Therapeutics Inc (NASDAQ: DMAC ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) ( announced mid-stage results of NASH treatment candidate) Enochian Biosciences Inc (NASDAQ: ENOB ) Erytech Pharma SA (NASDAQ: ERYP ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Gemphire Therapeutics Inc (NASDAQ: GEMP ) Gritstone Oncology Inc (NASDAQ: GRTS ) HTG Molecular Diagnostics Inc (NASDAQ: HTGM ) IGM Biosciences Inc (NASDAQ: IGMS ) (initial public offering on Sept. Read more
Here are two rare disease biotech concerns worth a good look, as Alexion Pharmaceuticals is a solid company that is the subject of acquisition rumors and Amicus Therapeutics has a key drug off to a strong start….ALXN Read more
Amicus' (FOLD) earnings meet estimates in the second quarter while revenues beat the same. Read more
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 0.00% and 7.32%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock? Read more
Amicus' shares shot up by 10.7% last month. Here's why. Read more
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Read more
Earnings and other concerns held some stocks back Thursday. Read more
The company announced a significant stock offering. Read more

Microcaps tops midday movers

04:52pm, Thursday, 30'th May 2019
Read more

2 Ultra-High-Growth Biotech Stocks to Buy Now

02:34pm, Thursday, 30'th May 2019
Amicus Therapeutics and Array BioPharma are two top growth stocks to consider buying now. Read more

Proudly made at